Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

28/04/2026 Eastern Time in USA The Dow Jones Industrial Average dropped by 0.05%, closing at 49141.93 points; the Nasdaq Composite dropped by 0.9%, closing at 24663.8 points; the S&P 500 Index dropped by 0.49%, closing at 7138.8 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

Kforce Inc.: Overnight gain 43.3%, Surges Amid Analyst Upgrades and Strong Quarterly Performance

Kforce Inc. is a global leader in professional technology staffing services, headquartered in Tampa, Florida. The company operates 59 branch offices across the United States and maintains an operational center in Manila, Philippines. Founded in 1994, Kforce Inc. traces its origins to Resource Services Inc. and Romac & Associates, which have been providing staffing services since 1962. The company completed its initial public offering in August 1995. Kforce Inc. delivers specialized workforce solutions through five business segments: Technology, Finance & Accounting, Field Services, Health Information Management, and Government Solutions. The company's strategic operations are organized across three geographic regions—Atlantic, North Central, and West—which coordinate the management of its Technology and Finance & Accounting divisions.

Kforce Inc. (KFRC) shares surged 43.3% following multiple positive catalysts converging simultaneously. William Blair upgraded the stock from "Market Perform" to "Outperform," while Baird raised its price target from $40 to $42, driving significant investor interest. The company's Q1 earnings exceeded expectations across key metrics. Revenue reached $330.4 million, surpassing estimates by $1.02 million and marking the first year-over-year growth since Q4 2022. Earnings per share of $0.46 beat analyst expectations of $0.41 by 12.2%. Gross margin improved to 27.3%, up 60 basis points year-over-year, demonstrating enhanced profitability. Market conditions are also improving, with the U.S. professional staffing market showing recovery signs and temporary staffing demand bottoming out. Kforce's AI business positioning has proven effective, with data and AI project pipelines growing nearly 50% year-over-year, and nearly 100% of current engagements incorporating AI elements. Management provided optimistic Q2 guidance, projecting approximately 4% revenue growth year-over-year, collectively boosting market confidence substantially.

Atlantic International Corp: Overnight gain 30.0%, Surges Amid Strategic AI Infrastructure Transformation Through Circle8 Group Acquisition

Atlantic International Corp (ATLN) Surges 30% on Strategic AI Infrastructure Pivot** Atlantic International Corp (ATLN) shares rallied 30% in a single session, extending year-to-date gains to 56.4%, following positive market reception of the company's strategic transformation through Circle8 Group. The company has successfully expanded into high-growth technology sectors including artificial intelligence infrastructure, cybersecurity, and data infrastructure—areas experiencing significant market momentum. Circle8 Group, valued at approximately $780 million as a European IT technology division, is injecting new momentum into Atlantic International Corp's (ATLN) $1.2 billion global platform. Leveraging premium enterprise and public sector client relationships across Europe and North America, management anticipates accelerated organic growth, substantial revenue increases, and enhanced long-term EBITDA margins. This comprehensive strategic initiative has transmitted strong growth signals to the market, boosting investor confidence and driving the dramatic share price appreciation. The transformation positions Atlantic International Corp (ATLN) advantageously within rapidly expanding technology verticals.

Edesa Biotech, Inc.: Overnight gain 27.7%, Surges Amid Positive Clinical Trial Progress for Core Drug Candidate

Edesa Biotech, Inc. was incorporated in September 1999 as a biopharmaceutical company focused on developing innovative therapies for inflammatory and immune-related diseases. The company employs a strategic approach to acquire, develop, and commercialize drug candidates based on mechanisms of action that have demonstrated proof-of-concept in human clinical trials. The company's lead asset is EB05 (paridiprubart), which represents the emerging class of host-directed therapies (HDT). These therapies are designed to modulate the human immune system's response mechanisms to infectious diseases and chemical agents, achieving therapeutic objectives through the regulation of the host's endogenous immune response.

**Edesa Biotech, Inc. (EDSA) Surges on Multiple Catalysts** Edesa Biotech, Inc. (EDSA) stock's remarkable ascent stems from multiple converging factors. The biopharmaceutical company, specializing in inflammatory and immune-related disorders, has achieved positive clinical progress with its lead candidate EB05 (paridiprubart), typically triggering significant biotech stock volatility. The company's host-directed therapy (HDT) approach represents an innovative treatment paradigm, particularly promising in infectious disease management, garnering substantial market attention. Edesa emphasizes its candidates are based on "mechanisms with proven proof-of-concept in human subjects," strengthening investor confidence in the technology platform. The company's small-cap biotech characteristics contribute to pronounced price movements, with the 904.2% year-to-date gain reflecting sector-wide volatility. The inflammatory immunotherapy space presents vast unmet medical needs, with markets optimistic about the company's development prospects. These milestone events in clinical development continue driving investor interest in Edesa's differentiated therapeutic approach.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team. Risk and Disclaimer: The content provided above is solely for informational purposes and does not represent the views or positions of Sahm Platform. While we strive for accuracy, we cannot guarantee the authenticity or completeness of the information contained in the provided content. We strongly recommend that investors consult with a qualified investment advisor when deemed necessary. Sahm Platform neither provides investment advice nor makes any representations or warranties concerning the accuracy, reliability, or completeness of the information in the content provided above. By using Sahm Platform, you acknowledge that you have read, understood, and agreed to the terms set forth in this disclaimer.